RedHill Biopharma (RDHL) Work In Process (2021 - 2024)

RedHill Biopharma (RDHL) has 4 years of Work In Process data on file, last reported at $308000.0 in Q4 2024.

• On a quarterly basis, Work In Process rose 32.19% year-over-year to $308000.0 in Q4 2024; TTM through Dec 2024 was $308000.0, a 32.19% increase from a year earlier, with the FY2024 full-year figure at $308000.0, up 32.19% from the prior year.
• Work In Process for Q4 2024 stood at $308000.0, up from $233000.0 in the prior quarter.
• Over the last five years, Work In Process for RDHL reached as high as $5.2 million in Q4 2021 and fell as low as $233000.0 in Q4 2023.
• Historically, Work In Process has averaged $2.0 million across 4 years, with a median of $1.3 million in 2022.
• Across the five-year window, Work In Process slumped 90.23% in 2023 and jumped 32.19% in 2024, its largest moves.
• Year by year, Work In Process stood at $5.2 million in 2021, then sank by 54.09% to $2.4 million in 2022, then slumped by 90.23% to $233000.0 in 2023, then soared by 32.19% to $308000.0 in 2024.
• Per Business Quant data, the three most recent Work In Process figures were $308000.0 in Q4 2024, $233000.0 in Q4 2023, and $2.4 million in Q4 2022.